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Oncogenes and inflammation rewire host energy
metabolism in the tumor microenvironment
RAS and NFkB target stromal MCT4
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Here, we developed a model system to evaluate the metabolic effects of oncogene(s) on the host microenvironment.
A matched set of “normal” and oncogenically transformed epithelial cell lines were co-cultured with human fibroblasts, to
determine the “bystander” effects of oncogenes on stromal cells. ROS production and glucose uptake were measured by
FACS analysis. In addition, expression of a panel of metabolic protein biomarkers (Caveolin-1, MCT1, and MCT4) was analyzed in parallel. Interestingly, oncogene activation in cancer cells was sufficient to induce the metabolic reprogramming of
cancer-associated fibroblasts toward glycolysis, via oxidative stress. Evidence for “metabolic symbiosis” between oxidative
cancer cells and glycolytic fibroblasts was provided by MCT1/4 immunostaining. As such, oncogenes drive the establishment of a stromal-epithelial “lactate-shuttle”, to fuel the anabolic growth of cancer cells. Similar results were obtained with
two divergent oncogenes (RAS and NFkB), indicating that ROS production and inflammation metabolically converge on
the tumor stroma, driving glycolysis and upregulation of MCT4. These findings make stromal MCT4 an attractive target
for new drug discovery, as MCT4 is a shared endpoint for the metabolic effects of many oncogenic stimuli. Thus, diverse
oncogenes stimulate a common metabolic response in the tumor stroma. Conversely, we also show that fibroblasts protect cancer cells against oncogenic stress and senescence by reducing ROS production in tumor cells. Ras-transformed
cells were also able to metabolically reprogram normal adjacent epithelia, indicating that cancer cells can use either fibroblasts or epithelial cells as “partners” for metabolic symbiosis. The antioxidant N-acetyl-cysteine (NAC) selectively halted
mitochondrial biogenesis in Ras-transformed cells, but not in normal epithelia. NAC also blocked stromal induction of
MCT4, indicating that NAC effectively functions as an “MCT4 inhibitor”. Taken together, our data provide new strategies for
achieving more effective anticancer therapy. We conclude that oncogenes enable cancer cells to behave as selfish “metabolic parasites”, like foreign organisms (bacteria, fungi, viruses). Thus, we should consider treating cancer like an infectious
disease, with new classes of metabolically targeted “antibiotics” to selectively starve cancer cells. Our results provide new
support for the “seed and soil” hypothesis, which was first proposed in 1889 by the English surgeon, Stephen Paget.

Introduction
Previous studies have shown that mutational activation
and/or overexpression of diverse oncogenes is indeed sufficient to
confer cell transformation and to drive tumor growth and metastasis in whole-animal models.1,2 This has led to the over-simplified
notion that cancer is a cell-autonomous disease. However, this

view is inherently incomplete, as it does not explain the critical role
of the tumor microenvironment or the host organism in tumor
initiation, progression, and metastasis.3-7 As such, a more global
or metabolic view of cancer will be necessary for us to begin to
design and implement new more effective anticancer therapies.8-11
Also, little is known regarding the process of tumor cell engraftment. We believe that understanding the metabolic requirements
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Figure 1. The HaCaT cell system: Immortalized and transformed with
oncogenes. HaCaT cells are immortalized epidermal keratinocytes, but
they are not transformed, and they do not form tumors in immunodeficient mice. However, overexpression of activated H-Ras (G12V) or NFkB
(p65 subunit) drives cell transformation, and confers the capacity for
tumor cell engraftment, leading to tumor formation in nude mice. Thus,
phenotypic comparisons of these 3 matched cell lines should allow one
to better understand the metabolic requirements for successful tumor
cell engraftment within the naïve host microenvironment.

for tumor cell engraftment should allow us to develop new strategies for cancer prevention and therapy. Tumor cell engraftment
most likely requires that the cancer cells gain the ability to metabolically reprogram their microenvironment, essentially a “nesting” type of cell behavior. In support of this notion, many human
epithelial tumor types consist of “cancer cell nests”, surrounded
by cancer-associated fibroblasts, which were originally thought to
play mainly a structural role.
However, more recent studies indicate that epithelial cancer
cells also derive many of their nutrients directly from cancer-associated fibroblasts and other stromal cells, such as adipocytes.12-54
This would be especially critical during the early phases of tumor
initiation and the later stages of metastasis, when a neo-angiogenic blood supply is clearly lacking. We have termed this type
of symbiotic relationship between cancer cells and stromal cells
“two-compartment tumor metabolism.”31,33,40,42-45 In this scenario,
glycolytic fibroblasts directly provide mitochondrial fuels (such as
L-lactate and ketone bodies) for oxidative cancer cells to burn
via the TCA cycle and OXPHOS. This energy transfer scheme
also requires the establishment of a stromal-epithelial “lactate
shuttle”, for the efficient transfer of these high-energy nutrients
from fibroblasts to cancer cells. To accomplish this metabolic coupling, fibroblasts export L-lactate and ketone bodies via MCT4
transporters.55,56 In turn, epithelial cancer cells import and recycle
these fuels via the MCT1 transporter to produce ATP efficiently.
So, how do we integrate the “oncogene theory” of cancer with
this new form of cancer metabolism or “metabolic symbiosis”?
One simple idea is that oncogenes give cancer cells the ability
to manipulate and/or sculpt their microenvironment for their
own personal benefit at a significant cost to the host organism.31
This would also mechanistically explain tumor cell engraftment.
Thus, oncogenes may give predatory cancer cells the ability to
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Figure 2. HaCaT-fibroblast co-cultures: Transformed HaCaT cells show a
modest increase in ROS production, without any significant increases in
glucose uptake. (A) ROS-production. (B) Glucose uptake. HaCaT epithelial
cells (control, H-Ras [G12V], or NFkB [p65]) were co-cultured for 4 days with
hTERT-immortalized fibroblasts (RFP[+]). Then, ROS production (a measure
of oxidative stress) and glucose uptake (a measure of glycolytic activity)
in HaCaT cells were quantitatively determined by FACS sorting. Note that
only HaCaT-Ras cells show a significant increase in ROS production (1.5fold; P = 0.03), without any detectable increases in glucose uptake.

function as “metabolic parasites”. This would mean that oncogenes in epithelial cancer cells must also have long-distance or
bystander effects on the tumor microenvironment in order for
cancer cells to make a proper nest.
Here, we have begun to test this new hypothesis using a
matched set of 3 well-defined epithelial cell lines.57 The parental
cell line (HaCaT cells) is immortalized, but not transformed, and
does not form tumors in nude mice, so it is incapable of cancer cell engraftment.58 The two other HaCaT cells lines we used
harbor activated oncogenes (H-Ras [G12V] or NFkB [p65]), are
transformed, and form tumors in nude mice, so they efficiently
undergo cancer cell engraftment. Interestingly, we show that
only HaCaT cells that harbor activated oncogenes gain the ability to glycolytically reprogram the tumor microenvironment, via
the induction of oxidative stress in cancer-associated fibroblasts.
Thus, it appears that oncogenes also act at a distance, via ROS
production and inflammation, to induce metabolic symbiosis
between cancer cells and the tumor stroma. As a consequence,
diverse oncogenes (Ras and NFkB) act via a common convergent
mechanism (oxidative stress) to upregulate MCT4 in the tumor
stroma. As MCT4 controls the “fuel supply” for cancer cells, this
makes MCT4 an extremely attractive druggable target for new
therapeutic interventions aimed at “starving” oncogenically activated tumor cells. As such, diverse oncogenes stimulate a common
metabolic response to “injury” in the tumor microenvironment.
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This idea is consistent with the hypothesis that cancer behaves as
a wound that does not heal.
N-acetyl-cysteine (NAC) is among the smallest FDA-approved
drug molecules currently in use, and it has both antioxidant and
anti-inflammatory properties. Surprisingly, however, it is not used
clinically for the treatment of human cancers. As we show here
that NAC inhibits the induction of stromal MCT4 by preventing
oxidative stress, this may also explain why NAC so effectively prevents tumor initiation, progression, and metastasis, in numerous
pre-clinical animal models.59-70 As such, new clinical trials with
NAC should be considered, to alleviate oxidative stress and inflammation in the tumor microenvironment. In addition, since NAC
effectively functions as an “MCT4 inhibitor”, the development of
more targeted and selective MCT4 inhibitors may be warranted.
Results
HaCaT cells: An experimental model for understanding the
requirements of tumor cell engraftment
HaCaT cells are considered to be a relatively “normal”, nontransformed, spontaneously immortalized human epithelial kerati-

Figure 3. HaCaT-fibroblast co-cultures: Cancer-associated fibroblasts
show dramatic increases in both ROS production and glucose uptake.
(A) ROS-production. (B) Glucose uptake. HaCaT epithelial cells (control,
H-Ras [G12V], or NFkB [p65]) were co-cultured for 4 days with hTERTimmortalized fibroblasts (RFP[+]). Then, ROS production (a measure of
oxidative stress) and glucose uptake (a measure of glycolytic activity) in
hTERT-fibroblasts were quantitatively determined by FACS sorting. Note
that hTERT-fibroblasts co-cultured with HaCaT-Ras cells show a significant
increase in both ROS production (2.5-fold; P = 0.008) and glucose uptake
(2.2-fold; P = 0.03). Similarly, hTERT-fibroblasts co-cultured with HaCaT-p65
cells show a significant increase in ROS production (1.9-fold; P = 0.01) and
glucose uptake (1.7-fold; P = 0.02). Thus, oncogene-transformed epithelial
cancer cells metabolically reprogram adjacent normal fibroblasts.
2582

nocyte cell line.58 In accordance with this idea, they fail to form
tumors in immunodeficient mouse animal models.58 Thus, they
are an ideal cell line to study the factors that are required for successful tumor cell engraftment. Indeed, several laboratories have
now shown that the recombinant expression of activated oncogenes
in HaCaT cells is sufficient to confer effective cell transformation
and tumor formation in nude mice. In this regard, expression of
either activated H-Ras (G12V) or the p65 subunit of NFkB in
HaCaT cells greatly facilitates successful tumor cell engraftment.57
Thus, this isogenic matched series of HaCaT cell lines (control, H-Ras [G12V], and NFkB [p65]) provides a unique, wellcharacterized model system to begin to dissect the possible
metabolic requirements for tumor formation and efficient epithelial tumor cell engraftment (Fig. 1).
For this purpose, we co-cultured HaCaT cells with hTERTimmortalized fibroblasts, to mimic and monitor their reciprocal
interactions with the host tumor microenvironment.
Ras activation and inflammation in epithelial cancer cells
metabolically alters the tumor microenvironment, driving stromal oxidative stress and glycolysis
To model and dissect the metabolic basis of tumor-stromal
interactions, epithelial HaCaT cells (control, H-Ras [G12V], and

Figure 4. Cancer-associated fibroblasts Show the largest increases in
ROS production and glucose uptake, as directly compared with adjacent
epithelial cancer cells. (A) ROS-production. (B) Glucose uptake. Data
originally presented in Figures 2 and 3 is presented again in Figure 4, in
another format. In this case, the absolute magnitude of ROS production
and glucose uptake in epithelial cancer cells and fibroblasts is directly
compared, side-by-side, on the same graphs. This allows one to better
appreciate that although the epithelial cancer cells harbor the activated
oncogenes, their largest effects on cellular metabolism actually occur in
neighboring normal fibroblasts. Thus, the “bystander” effect of oncogenes on the tumor microenvironment is one of the most significant
metabolic effects, in terms of metabolic reprogramming.
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NFkB [p65]) were co-cultured with immortalized fibroblasts and
then subjected to FACS analysis with a series of fluorescent metabolic probes. These small reporter molecules allowed us to quantitatively monitor ROS production (a measure of oxidative stress)
and glucose uptake (a measure of glycolysis or glycolytic power) in
a compartment-specific fashion. Thus, we compared ROS production and glucose uptake in epithelial cancer cells and adjacent normal fibroblasts to determine how epithelial oncogene activation
metabolically reprograms the tumor stromal microenvironment.
Figure 2A and B show the status of these metabolic parameters in HaCaT cells co-cultured with fibroblasts. Interestingly,
Ras activation leads to a 1.5-fold increase in ROS production, as
expected based on the literature. However, NFkB activation did
not increase ROS production significantly. Moreover, oncogeneactivation (Ras or NFkB) did not result in increased glucose
uptake. Thus, the metabolic effects of oncogene activation in epithelial cancer cells appeared to be relatively minimal.
Next, we examined ROS production and glucose uptake in the
population of hTERT fibroblasts co-cultured with HaCaT cells
(Fig. 3A and B). Large metabolic changes were observed in both

Figure 5. Ras oncogene activation and inflammation drive a loss of Cav-1
expression in adjacent cancer-associated fibroblasts. (A) HaCaT epithelial cells (control, H-Ras [G12V], or NFkB [p65]) were co-cultured for 4 days
with hTERT-immortalized fibroblasts (GFP+). Then, the cells were fixed
and immunostained with specific antibody probes. Note that a loss of
stromal Cav-1 occurs only in fibroblasts co-cultured with HaCaT-Ras and
HaCaT-p65 cells. HaCaT control cells did not induce a loss of Cav-1 in stromal fibroblasts. DAPI (blue nuclear staining) is also shown for reference.
(B) Image quantitation regarding the oncogene-induced loss of stromal
Cav-1 is presented; note that there is a significant 2–3-fold reduction in
Cav-1 expression.
www.landesbioscience.com

Figure 6. Ras oncogene activation and inflammation drive the upregulation of MCT4 expression in adjacent cancer-associated fibroblasts. (A)
HaCaT epithelial cells (control, H-Ras [G12V], or NFkB [p65]) were co-cultured for 4 days with hTERT-immortalized fibroblasts (GFP+). Then, the
cells were fixed and immunostained with specific antibody probes. Note
that MCT4 expression is increased most significantly in fibroblasts cocultured with HaCaT-Ras and HaCaT-p65 cells. In contrast, HaCaT control
cells only induced a mild or modest increase in stromal MCT4 expression. DAPI (blue nuclear staining) is also shown for reference. (B) Image
quantitation regarding the oncogene-induced upregulation of stromal
MCT4 at day 4 is presented; note that there is a significant 3-fold upregulation of MCT4 expression. P values vs. fibroblasts alone (P < 0.0007) and
vs. HaCaT-CTRL co-cultures (P < 0.004) are both shown. (C) Image quantitation regarding the oncogene-induced upregulation of stromal MCT4
at day 5 is presented; note that there is a significant 4-fold upregulation of MCT4 expression. P values vs. fibroblasts alone (P < 0.01) and
vs. HaCaT-CTRL co-cultures (P < 0.001) are both shown.
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ROS production and glucose uptake. More specifically, hTERTfibroblasts co-cultured with HaCaT-Ras cells showed a significant
increase in both ROS production (2.5-fold; P = 0.008) and glucose uptake (2.2-fold; P = 0.03). Similarly, hTERT-fibroblasts cocultured with HaCaT-p65 cells showed a significant increase in
ROS production (1.9-fold; P = 0.01) and glucose uptake (1.7-fold;

P = 0.02). Thus, oncogene-transformed epithelial cancer cells
metabolically reprogram adjacent normal fibroblasts.
Cancer-associated fibroblasts produce more ROS and are
more glycolytic, as directly compared with epithelial cancer cells
Figure 4 shows the absolute magnitude of ROS production
and glucose uptake in epithelial cancer cells and fibroblasts. This
direct, side-by-side comparison allows one to appreciate that
although the epithelial cancer cells harbor the activated oncogenes, their largest effects on cellular metabolism are actually
occurring in neighboring normal fibroblasts.
Thus, the “bystander” effect of oncogenes on the tumor microenvironment appears to be one of the most significant metabolic
effects, in terms of metabolic reprogramming.
Ras oncogene activation and inflammation drive a loss of stromal Cav-1 expression in adjacent cancer-associated fibroblasts
Loss of stromal caveolin-1 (Cav-1) is a biomarker of poor clinical outcome in several distinct types of human epithelial cancers,
including breast, prostate, and gastric carcinomas, as well as in
metastatic melanoma.71-82 In human breast cancers, reductions
in stromal Cav-1 are clinically associated with early tumor recurrence, lymph-node metastasis, tamoxifen-resistance, and premature death. Mechanistically, loss of Cav-1 occurs via autophagic/
lysosomal degradation due to oxidative stress in cancer-associated
fibroblasts.30 Thus, loss of stromal Cav-1 is a functional biosensor of oxidative stress, autophagy, and glycolysis in the tumor
microenvironment.22,34
As a consequence, we next examined the ability of HaCaT
cells to downregulate Cav-1 expression in normal adjacent fibroblasts, during co-culture. For this purpose, HaCaT epithelial
cells (control, H-Ras [G12V], or NFkB [p65]) were co-cultured with hTERT-immortalized fibroblasts (GFP[+]). Then,
the cells were fixed and immunostained with specific antibody
probes. Figure 5A shows that loss of stromal Cav-1 occurs only
in fibroblasts co-cultured with HaCaT-Ras and HaCaT-p65 cells.
However, HaCaT control cells did not induce a loss of Cav-1 in
stromal fibroblasts. Image quantitation regarding the oncogeneinduced loss of stromal Cav-1 is presented in Figure 5B. Note
that there is a significant 2–3-fold reduction in Cav-1 expression.
Thus, a loss of stromal Cav-1 is essentially a “mirror” or
“reporter” of oncogenic transformation in adjacent epithelial cancer cells during the transition to malignancy.
Ras oncogene activation and inflammation drive the upregulation of MCT4 expression in adjacent cancer-associated
fibroblasts, via oxidative stress
Like Cav-1, MCT4 is another biomarker of oxidative stress
in cancer-associated fibroblasts.55,56 In head and neck cancers,
Figure 7. Oxidative stress mediates the upregulation of MCT4 in cancerassociated fibroblasts: rescue with NAC, a powerful antioxidant. HaCaT
epithelial cells (control, H-Ras [G12V], or NFkB [p65]) were co-cultured for
5 days with hTERT-immortalized fibroblasts (GFP+). Then, the cells were
fixed and immunostained with specific antibody probes. Note that MCT4
expression is increased most significantly in fibroblasts co-cultured with
HaCaT-Ras cells and HaCaT-p65 cells, and that this can be reversed or
prevented by the addition of the powerful antioxidant, N-acetyl cysteine (NAC) [10 mM], to the culture media. (A) HaCaT control co-cultures;
(B) HaCaT-Ras co-cultures; (C) HaCaT-p65 co-cultures. DAPI (blue nuclear
staining) is also shown for reference.
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MCT4 is a highly specific marker of cancer-associated fibroblasts, as compared with normal fibroblasts.83 In addition, stromal MCT4 expression in triple-negative breast cancers is a single
independent powerful predictor of poor clinical outcome.84 In
this context, a loss of stromal Cav-1 is strictly correlated with
stromal MCT4 upregulation and lethality in triple-negative
breast cancer patients.84 Physiologically, MCT4 allows the efficient export of L-lactate and ketone bodies from glycolytic cells.
Mechanistically, MCT4 is a HIF1-α target gene that is upregulated under conditions of hypoxia and/or oxidative stress (a.k.a.,
pseudo-hypoxia). Hence, MCT4 is a functional biomarker of
oxidative stress, hypoxia, and glycolysis, as well as mitochondrial
dysfunction.
As such, we next examined the ability of HaCaT cells to upregulate MCT4 expression in normal adjacent fibroblasts during coculture. HaCaT epithelial cells (control, H-Ras [G12V] or NFkB
[p65]) were co-cultured with hTERT-immortalized fibroblasts
(GFP+). Then, the cells were fixed and immunostained with
specific antibody probes. Figure 6A shows that MCT4 expression is increased most significantly in fibroblasts co-cultured with
HaCaT-Ras and HaCaT-p65 cells. In contrast, HaCaT control
cells only induce a mild or modest increase in stromal MCT4
expression, close to the “border” or epithelial-stromal interface.
Image quantitation regarding the oncogene-induced upregulation of stromal MCT4 is presented in Figure 6B and C. Note
that stromal MCT4 expression is increased by up to > 4-fold during fibroblast co-culture with HaCaT-Ras and HaCaT-p65 cells.
To directly validate the idea that increased MCT4 expression
represents oxidative stress in cancer-associated fibroblasts, we
explored the functional effects of N-acetyl cysteine (NAC) [10
mM], a powerful antioxidant. Indeed, Figure 7 shows that NAC
treatment reversed or prevented the induction of MCT4 in the
stromal microenvironment in Ras and NFkB co-cultures only,
directly implicating oxidative stress. Quantitation of these findings is presented in Figure 8A and B. Note that NAC treatment
normalizes MCT4 expression in HaCaT-Ras and HaCaT-p65
co-cultures. Thus, NAC effectively functions as an “MCT4
inhibitor”.
Co-culture with fibroblasts upregulates the expression of
MCT1 in Ras-transformed and NFkB-expressing epithelial
cancer cells: Establishment of metabolic symbiosis
We have previously provided evidence that a “lactate shuttle”
exists in human tumors.45,55,56,83 In this scenario, cancer-associated fibroblasts express MCT4 and export mitochondrial fuels
(such as L-lactate and ketone bodies) into the tumor microenvironment. Conversely, epithelial cancer cells express MCT1,
which allows them to efficiently import these mitochondrial fuels
to “burn” as an energy source for oxidative mitochondrial metabolism. This metabolic symbiosis mechanism could represent how
tumor cells achieve efficient engraftment by metabolically cooperating with and rewiring their host microenvironment. To
further test this hypothesis, we next examined the expression of
MCT1 in HaCaT cells, either cultured alone or in the presence
of stromal fibroblasts.
More specifically, HaCaT epithelial cells (control,
H-Ras [G12V], or NFkB [p65]) were co-cultured with
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hTERT-immortalized fibroblasts (GFP[+]). Alternatively,
HaCaT cells were cultured alone (without fibroblasts) for the
same amount of time. Then, the cells were fixed and immunostained with specific antibody probes.
Figure 9 shows that MCT1 expression and plasma membrane
localization is increased most significantly in HaCaT-Ras cells
and HaCaT-p65 cells co-cultured with fibroblasts, relative to the
same HaCaT cells cultured alone. Thus, induction of MCT1
in epithelial cancer cells is a functional biomarker of “metabolic symbiosis”, which occurs during co-culture with stromal
fibroblasts.
Interestingly, we have previously shown that MCT1 is a biomarker of increased mitochondrial mass and activity, as well as
high proliferation rates in vivo.83 For example, MCT1 expression is tightly correlated with Ki-67 immunostaining in head and
neck cancers and in normal mucosal tissues, especially within
the basal stem cell compartment.83 Thus, MCT1 may also be a
marker of increased stem cell activity.

Figure 8. NAC quantitatively reduces oncogene-induced expression
of MCT4 in cancer associated fibroblasts. (A) HaCaT-Ras co-cultures; (B)
HaCaT-p65 co-cultures. MCT4 expression, illustrated in Figure 7, was subjected to image quantitation, as detailed under “Materials and Methods”.
Note that HaCaT-Ras and HaCaT-p65 cells significantly induce MCT4
expression in adjacent stromal fibroblasts, during co-culture. However,
treatment with NAC [10 mM] reduced stromal MCT4 expression levels by
nearly 3-fold, approaching baseline levels. Thus, NAC effectively functions as an “MCT4 inhibitor”.
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Figure 9. Co-culture with fibroblasts upregulates the expression of
MCT1 in Ras-transformed and NFkB-expressing epithelial cells. HaCaT
epithelial cells (control, H-Ras [G12V], or NFkB [p65]) were co-cultured for
5 days with hTERT-immortalized fibroblasts (GFP+). Alternatively, HaCaT
cells were cultured alone (without fibroblasts) for the same amount of
time. Then, the cells were fixed and immunostained with specific antibody probes. Note that MCT1 expression and plasma membrane localization is increased most significantly in HaCaT-Ras cells and HaCaT-p65
cells co-cultured with fibroblasts, relative to the same HaCaT cells cultured alone. Insets at higher magnification are shown to highlight the
plasma membrane staining of MCT1. DAPI (blue nuclear staining) is also
shown for reference.

Homotypic cultures of epithelial cancer cells show that
Ras transformation increases ROS production and MCT4
expression
For comparison purposes, we also examined some of the metabolic properties of HaCaT cells cultured alone under homotypic

2586

culture conditions. For this purpose, HaCaT epithelial cells
(control, H-Ras [G12V], or NFkB [p65]) were cultured alone
and then subjected to either FACS analysis to determine ROS
production, or immunostaining with antibodies directed against
MCT4, a marker of oxidative stress.
Interestingly, Figure 10 shows that Ras-activation in
HaCaT cells significantly increases ROS production (Fig. 10A;
1.5-fold; P = 0.02) and MCT4 expression at the plasma membrane (Fig. 10B). Thus, HaCaT-Ras cells cultured alone also
show an increase in oxidative stress. In contrast, HaCaT-p65 cells
did not show significant evidence of oxidative stress when cultured alone. Thus, they may induce oxidative stress in fibroblasts
via cytokine production.
Importantly, co-culture of normal and epithelial cancer cells
with fibroblasts reduced ROS-production in all cases, indicating that fibroblasts may help induce an antioxidant response in
adjacent epithelial cells and protect epithelial cells from oxidative stress (Fig. 10C). These findings are consistent with recent
studies showing that bone marrow-derived stromal cells provide
cysteine (cys), which is transferred to cancer cells (in chronic
lymphocytic leukemia [CLL]) and is then converted to glutathione (gamma-glut-cys-gly), fueling an antioxidant response.85
Oncogene activation can drive the upregulation of mitochondrial activity in epithelial cancer cells
We also examined the functional effects of oncogenic transformation on the status of mitochondria in epithelial cancer
cells. Briefly, HaCaT epithelial cells (control, H-Ras [G12V], or
NFkB [p65]) were cultured alone and then subjected to FACS
analysis to determine mitochondrial activity, via MitoTracker
staining.
Figure 11 shows that HaCaT-Ras cells (1.5-fold; P = 0.009)
and HaCaT-p65 cells (1.6-fold; P = 0.006) both show a significant increase in MitoTracker activity staining. Thus, oncogenic
tranformation can also promote increases in mitochondrial
mass and/or activity in epithelial cancer cells, so that they are
“primed” to undergo metabolic symbiosis with a glycolytic stromal microenvironment.
Antioxidants inhibit mitochondrial biogenesis in Rastransformed cancer cells
We also followed mitochondrial mass in HaCaT using a specific mitochondrial marker, namely TOMM20, which also serves
as a marker of mitochondrial biogenesis. In these studies, HaCaT
epithelial cells (control, H-Ras [G12V], or NFkB [p65]) were
cultured alone (in the absence or presence of NAC [10 mM]) and
then subjected to immunostaining with TOMM20.
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Figure 10. Homotypic cultures of epithelial cancer cells show that Rastransformation increases ROS production and MCT4 expression. HaCaT
epithelial cells (control, H-Ras [G12V], or NFkB [p65]) were cultured alone
and then subjected to either FACS analysis to determine ROS production
(A), or immunostaining with antibodies directed against MCT4, a marker
of oxidative stress (B). Note that Ras-activation in HaCaT cells significantly increases ROS production (1.5-fold; P = 0.02) and MCT4 expression
plasma membrane staining. DAPI (blue nuclear staining) is also shown
for reference. (C) shows ROS production in HaCaT epithelial cells (control,
H-Ras [G12V], or NFkB [p65]) alone or during co-culture with fibroblasts,
by comparing data presented in Figure 2 and Figure 10A; these data
are derived from the same experiments. Note that co-culture of normal
and epithelial cancer cells with fibroblasts reduced ROS-production
in all cases, indicating that fibroblasts may help induce an antioxidant
response in adjacent epithelial cells and protect these epithelial cells
from oxidative stress.

Figure 12 illustrates that HaCaT-Ras cells show the most
significant increases in mitochondrial mass (consistent with the
MitoTracker data), and that this is strictly dependent on oxidative
stress. Note that NAC treatment almost completely eliminated
mitochondrial staining in HaCaT-Ras, but had little or no effect
on mitochondrial mass in HaCaT-p65 cells and control HaCaT
cells. As such, it appears that NAC selectively halts mitochondrial
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biogenesis in Ras-transformed cells, possibly explaining how
antioxidants could be used to “starve” cancer cells. Image quantitation revealed that the expression of TOMM20 was reduced
by >5-fold in NAC-treated HaCaT-Ras cells (data not shown).
Thus, ROS production in HaCaT-Ras cells apparently drives
mitochondrial biogenesis in epithelial cancer cells, and then
almost simultaneously “fertilizes” the tumor microenvironment,
via “bystander” oxidative stress in cancer-associated fibroblasts.
Fibroblasts protect cancer cells against programmed cell
death
As fibroblasts appeared to protect HaCaT-Ras and HaCaT-p65
cells against oxidative stress (Fig. 10C), we also examined their
effects on programmed cell death (apoptosis), which was quantitated by FACS analysis using Annexin-V and PI staining.
Figure 13A shows that fibroblasts did not affect cell death in
normal HaCaT control cells but significantly rescued HaCaTRas and HaCaT-p65 cells from apoptosis. However, the most
significant fibroblast-mediated reductions in programmed cell
death were observed with HaCaT-Ras cells, which showed a 2.4fold reduction in apoptosis.
Thus, fibroblasts functionally rescue HaCaT-Ras and
HaCaT-p65 cells from oxidative stress and programmed cell
death, likely by reducing oncogene-induced stress.
Fibroblasts confer resistance to autophagy and senescence
during Ras activation in cancer cells
Previously, we and others have shown that β-galactosidase
(β-GAL) is a metabolic marker of both autophagy and senescence, as it is a key lysosomal enzyme which accumulates in lysosomes and autophagosomes in senescent cells.49-51,54
Since fibroblasts effectively reduced oxidative stress and protected cancer cells against apoptosis, we also speculated that
these reductions in oxidative stress may also protect HaCaTRas cells against autophagy and senescence. HaCaT-Ras cells
should be particularly susceptible to autophagy and senescence,
as H-Ras (G12V) expression is known to confer significant oncogenic stress. Thus, we quantitatively measured β-galactosidase
(β-GAL) activity levels by FACS analysis.
First, we examined β-GAL activity in HaCaT cells (CTRL
vs. Ras). These results are shown in Figure 13B and C. Note
that HaCaT-Ras cells cultured alone showed very dramatic
increases in β-GAL activity, as compared directly with HaCaT
control cells. However, β-GAL levels were progressively reduced
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Figure 11. Ras oncogene activation and inflammation both drive the
upregulation of mitochondrial activity in epithelial cancer cells. HaCaT
epithelial cells (control, H-Ras [G12V], or NFkB [p65]) were cultured alone
and then subjected to FACS analysis to determine mitochondrial activity,
via MitoTracker staining. Note that HaCaT-Ras cells (1.5-fold; P = 0.009)
and HaCaT-p65 cells (1.6-fold; P = 0.006) both show a significant increase
in MitoTracker activity staining.

(by >2-fold) in HaCaT-Ras cells during co-culture with hTERTimmortalized fibroblasts over a 2–4 day period.
This provides independent support for the idea that cancer
cells use fibroblasts to rescue themselves from oncogene-induced
stress and to confer autophagy resistance and suppress senescence
in cancer cells.
Ras activation in cancer cells significantly alters metabolism
in normal adjacent epithelial cells, driving oxidative stress and
glycolysis
To determine if Ras activation in epithelial cancer cells
also affects metabolism in normal adjacent epithelial cells,
HaCaT-Ras (RFP[+]) cells were co-cultured with normal
HaCaT control cells, which are not transformed. Then, these
epithelial–epithelial co-cultures were subjected to FACS analysis with a series of fluorescent metabolic probes. These small
reporter molecules allowed us to quantitatively monitor ROS
production (a measure of oxidative stress) and glucose uptake
(a measure of glycolysis or glycolytic power) in a compartmentspecific fashion. Thus, we compared ROS production and
glucose uptake in Ras-transformed epithelial cancer cells and
adjacent “normal” epithelial cells to determine how epithelial
oncogene-activation metabolically reprograms adjacent normal
epithelial cells.
Figure 14 shows the status of these metabolic parameters
in normal HaCaT control cells co-cultured with HaCaT-Ras
(RFP[+]) cells. More specifically, we examined ROS production
and glucose uptake in the population of normal HaCaT control
cells co-cultured with HaCaT-Ras cells. Significant changes were
observed in both ROS production and glucose uptake. More specifically, normal HaCaT control cells that were co-cultured with
HaCaT-Ras cells showed a significant increase in both ROS production (1.7-fold; P = 0.03) and glucose uptake (1.3-fold; P = 6
× 10−5). Thus, oncogene-transformed epithelial cancer cells can
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metabolically reprogram normal adjacent epithelial cells as well
as fibroblasts.
In contrast, normal HaCaT control cells did not change ROS
production or glucose uptake in HaCaT-Ras cells, indicating that
HaCaT-Ras cells exert a significant dominant effect over normal
epithelial cells. Thus, unlike fibroblasts, normal epithelial cells
do not relieve oxidative stress in epithelial cancer cells. This is an
important distinction, which suggests that fibroblasts also make
better partners for metabolic symbiosis.
We conclude that epithelial cancer cells can use either adjacent
fibroblasts, or even adjacent normal epithelial cells, as “partners”
to engage in a form of “metabolic symbiosis”.
Thus, as previously proposed by Sonveaux, Feron, and
Dewhirst, a “lactate shuttle” may also exist between two populations of oxidative and glycolytic epithelial cells.86-88 This occurs
clinically in head and neck cancers, where the oxidative cancer
cells with functional mitochondrial are hyper-proliferative and
are MCT1(+)-positive.83 In contrast, the glycolytic cancer cells
are mitochondria-deficient, non-proliferative, and are MCT4(+)positive.83 As such, this glycolytic cancer cell population may
actually represent relatively “normal” epithelial cells, which are
helping to fuel their neighbors via metabolic symbiosis. In fact,
these glycolytic MCT4(+) epithelial tumor cells appeared to be
well differentiated in head and neck cancers.83
Discussion
Cancer is a systemic metabolic disease, fueled by oxidative
stress and inflammation
Here, we provide provocative new evidence that cancer is not a
cell autonomous disease, but rather it is a systemic disease, of the
host stromal microenvironment (Fig. 15A). More specifically, we
show that RAS oncogene-induced ROS production is transmitted from epithelial cancer cells to neighboring normal fibroblasts.
As a consequence, epithelial ROS production drives the onset of
the cancer-associated fibroblast phenotype, resulting in an amplification of ROS production, literally creating a “field of oxidative
stress”. This has important functional consequences, as ROS production in cancer-associated fibroblasts causes a shift toward aerobic glycolysis, initiating the “reverse Warburg effect.”33,40,41,84,89
This fibroblastic shift toward glycolysis was quantitatively followed by FACS analysis and NBD–glucose uptake.
Virtually identical results were obtained using epithelial
cancer cells that were genetically reprogrammed toward a proinflammatory phenotype, via NFkB activation. As such, oncogene-induced ROS production and/or inflammation have similar
negative metabolic effects on the host microenvironment, allowing for effective tumor cell engraftment.
Our results explain how activated oncogenes, inflammation,
and ROS production “collaborate”, resulting in tumor initiation
and “fertilization” of the host microenvironment.18,19,35,38 Thus,
activated oncogenes and chronic inflammation have local and
systemic metabolic effect(s), which establish metabolic symbiosis between epithelial cancer cells and cancer-associated fibroblasts.17-19 This metabolic reprogramming results in the paracrine
establishment of “two-compartment tumor metabolism”90-92.
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Our findings have important practical applications
for changing the existing paradigm(s) of cancer diagnosis, FDG-PET-imaging, and anticancer therapy
toward more holistic and non-toxic approaches.18,25
They also directly implicate the use of antioxidants
and anti-inflammatory therapies in cancer prevention
and personalized medicine.42-45,93
Hence, cancer may be viewed as a host-based disease of chronic oxidative stress and inflammation that
starts locally as a point source in the cancer cell, which
is then amplified and spreads systemically in the host,
ultimately driving whole-body catabolism and “metabolic catastrophe” or “metabolic collapse”, especially
during metastasis.
Diverse oncogenic stimuli converge on a common druggable target: MCT4 in the tumor
microenvironment
Cancer cells use oncogene-driven oxidative stress
as a “weapon” to induce a specific metabolic response
to injury in the tumor microenvironment, allowing
Figure 12. Antioxidant treatment selectively inhibits mitochondrial biogenesis in
them to establish metabolic symbiosis and successful
Ras-transformed epithelial cancer cells. HaCaT epithelial cells (control, H-Ras [G12V],
or NFkB [p65]) were cultured alone (in the absence or presence of NAC [10 mM]) and
cancer cell engraftment within the host organism. In
then subjected to immunostaining with TOMM20, a marker of mitochondrial mass.
many ways, our current results are consistent with the
Note that HaCaT-Ras cells show the most significant increase in mitochondrial mass,
“seed and soil” hypothesis, which was originally proand that this is strictly dependent on oxidative stress. DAPI (blue nuclear staining) is
posed in 1889, by Dr Stephen Paget in England, more
also shown for reference.
than 100 y ago.94-97
We conclude that oncogenes can also act at a distance, via ROS production and inflammation, to induce meta- family of antibiotics, selectively kills cancer cells (but not normal
bolic symbiosis between cancer cells and the tumor stroma. cells), by preventing mitochondrial biogenesis in cancer cells.100
Diverse oncogenes (Ras and NFkB) may act via a common Furthermore, doxycyline, another tetracycline family member,
convergent mechanism (oxidative stress), to upregulate MCT4 inhibits breast cancer metastasis by >70% in pre-clinical animal
in the tumor stroma (Fig. 15B). In addition, we have previously models,101 likely by targeting mitochondrial protein synthesis in
shown that several other pro-oncogenic stimuli, such as loss of cancer cells.102
BRCA1,20,21 TGF-β secretion,98 and ethanol treatment,99 as well as
In accordance with these findings, we have previously shown
ROS and hydrogen peroxide (H2O2) production,56 all converge on that 15 markers of mitochondrial biogenesis are increased in
Cav-1 downregulation and MCT4 upregulation in the tumor stro- human breast cancer cells in vivo (e.g., TOMM20, MCT1, MRP
mal compartment. As such, changes in the expression of stromal [mitochondrial ribosomal proteins]),93 and that the overexpresCav-1/MCT4 can be used to monitor the transition to malignancy sion of genes that functionally drive mitochondrial biogenesis
during tumor initiation and progression. Taken together, these (GOLPH3, PGC1a/b, MitoNEET, or POLRMT) 91,92 in breast
data make stromal MCT4 an attractive new druggable target for cancer cells is indeed sufficient to increase tumor growth rates in
novel therapeutic interventions, as MCT4 controls the “food” sup- xenografted mice.
ply for cancer cells.56,83,84
Interestingly, we also show here that NAC halts mitochondrial
In summary, oncogenic stress stimulates a common metabolic biogenesis in Ras-transformed epithelial cancer cells, most likely
response to “injury” in the tumor microenvironment. This idea by eliminating oxidative stress. Thus, NAC targets both epitheis consistent with the hypothesis that cancer behaves as a wound lial cancer cells and the tumor microenvironment, “hitting” multiple genetic and spatial targets at the same time.
that does not heal (Fig. 16).
Inflammation is a critical mediator of the transition to
Cancer cells behave as “metabolic parasites”: Can we treat
malignancy: Implications for chemoprevention with anticancer like an infectious disease with “metabolic” antibiotics?
The parallels with infectious disease are now clear. Cancer cells inflammatory drugs
It has long been suggested that chronic inflammation (due
behave as predatory “metabolic parasites”, just like foreign microorganisms (bacteria, fungi, and viruses).31,36,40,44 Thus, we should to injury or infections), may be a critical trigger for tumor iniconsider treating cancer like an infectious disease, with new tiation.103,104 In accordance with this notion, the most comclasses of “metabolic” antibiotics that can starve cancer cells to mon global causes of cancer are due to infections in the cervix
death.
(HPV), liver (HBV), lung (TB), nasopharyngeal tissues (EBV),
Some of these “metabolic” antibiotics may already be avail- and stomach (H. pylori). In addition, other chronic inflammaable. For example, tigecycline, a member of the tetracycline tory conditions, such as ulcerative colitis, Crohn disease, and
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Figure 13. Fibroblasts protect cancer cells against
apoptosis, autophagy, and sensecence: quantitation via FACS. (A) Apoptosis. Cell death was
quantified by flow cytometry using propidium
iodide and Annexin-V-APC. After a total of 4 days
in culture, the cells were collected by centrifugation. Then, the annexin V-APC conjugate and
propidium iodide was added. Cells were then
analyzed by flow cytometry. Note that fibroblasts
(GFP[+]) did not affect cell death in HaCaT control cells, but significantly rescued HaCaT-Ras and
HaCaT-p65 cells from apoptosis. However, the most
significant fibroblast-mediated reductions in cell
death were observed with HaCaT-Ras cells, which
showed a 2.4-fold reduction in apoptosis. (B and
C) Autophagy and senescence. Cells were treated
using the FluoReporter lacZ Flow Cytometry Kit
(Molecular probes). Assay results were evaluated by
flow-cytometry analysis. Note that HaCaT-Ras cells
cultured alone showed very dramatic increases in
β-GAL activity, as compared directly with HaCaT
control cells. However, β-GAL levels were progressively reduced (by >2-fold) in HaCaT-Ras cells
during co-culture with hTERT-immortalized fibroblasts, over a 2–4 d period. Thus, fibroblasts induce
autophagy-resistance and reverse senescence in
HaCaT-Ras cancer cells. (B) Day 2 co-culture; (C) day
4 co-culture.

scleroderma, all lead to an increased risk of developing cancer.
Moreover, in the GI tract, ROS-producing bacteria have been
implicated in the initiation of colon cancer. Finally, H. pylori
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also increases ROS (hydrogen peroxide) and
RNS (nitric oxide) in the stomach.
Notably, in DCIS patients, loss of stromal
Cav-1 is directly associated with inflammation in the tumor stroma.71 More specifically,
in this patient cohort, either loss of stromal
Cav-1 or inflammation were both individually sufficient to predict DCIS recurrence
and progression to invasive breast cancer.71
Importantly, loss of stromal Cav-1 was a better
predictor (as compared with inflammation) of
DCIS recurrence and/or progression, indicating that glycolytic stromal metabolism is the
most critical event for tumor progression.71
Similarly, we have shown here that oncogenes and inflammation induce a loss of
Cav-1, as well as increased oxidative stress,
and glycolysis in the host microenvironment.
This leads to metabolic symbiosis between
oxidative cancer cells and glycolytic stromal
fibroblasts. Thus, inflammation is a critical
mediator of tumor initiation and progression,
suggesting that we should consider new antiinflammatory strategies for chemoprevention,
and as anticancer therapies.
Understanding the desmoplastic reaction, during the transition to malignancy:
Implications for cancer therapy
The “desmoplastic reaction” refers to the
growth of connective
tissue fibroblasts or stroma in and around an area, usually
in response to an injury or the presence of a focus of cancer
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Figure 14. HaCaT epithelial-cancer cell co-cultures: Oncogene-transformed cancer cells can metabolically reprogram normal adjacent epithelial cells.
(A) ROS-production. (B) Glucose uptake. HaCaT-Ras (RFP[+]) epithelial cancer cells were co-cultured for 4 days with normal HaCaT control cells. Then,
ROS production (a measure of oxidative stress) and glucose uptake (a measure of glycolytic activity) in both cell types were quantitatively determined
by FACS sorting. Note that normal HaCaT control cells co-cultured with HaCaT-Ras cells show a significant increase in both ROS production (1.7-fold;
P = 0.03) and glucose uptake (1.3-fold; P = 6 × 10 −5). However, normal HaCaT control cells did not change ROS production or glucose uptake in HaCaT-Ras
cells, indicating that HaCaT-Ras cells exert a significant dominant effect over normal epithelial cells. Thus, oncogene-transformed epithelial cancer cells
can metabolically reprogram adjacent normal epithelial cells, to establish “metabolic symbiosis”.

cells.15,105-107 Thus, the desmoplastic reaction is part of the normal
wound response and is consistent with the notion that a tumor is
a wound that does not heal.105
In tumors, the desmoplastic reaction is most often associated with myo-fibroblastic differentiation and the increased
secretion of extracellular matrix proteins, such as collagen I and
tenascin C, among others.108 This can also lead to scar formation. Interestingly, tumors with a “central scar” or “fibrotic focus”
are associated with a worse clinical outcome, such as recurrence,
metastasis, and poor overall survival.109-114
Given our current findings, a new function for the desmoplastic reaction, which is a common feature of many different types
of malignancies, may be to help cancer cells overcome oncogenic
stress. More specifically, we show here that glycolytic stromal
fibroblasts reduce oxidative stress in cancer cells, which effectively protects these cancer cells against apoptosis, autophagy,
and even senescence.
Indeed, over the years, it has proved quite difficult to generate
new cancer cells lines, in addition to the NCI-60 panel of tumor
cells. One possible explanation is that primary cancer cells suffer
from oncogene-induced senescence, and that this becomes most
apparent when we isolate cancer cells away from stromal cells in
an attempt to have pure cultures of cancer cells. Thus, the best
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way to kill primary cancer cells may be to separate them from
stromal fibroblasts.
As such, new therapies should be developed to target the tumor
stroma. Once stromal cells are effectively killed, an expected consequence would be the onset of oncogene-induced senescence in
the primary cancer cells, resulting in tumor regression.
Materials and Methods
Materials
Antibodies were as follows: MCT4 and MCT1 (generous
gifts of Dr Nancy Philp, which are isoform-specific rabbit polyclonal antibody against 18-mer synthetic oligo-peptides corresponding to the C-terminal amino acids of human MCT4 or
MCT1115); TOMM20 (sc-17764, Santa Cruz Biotechnologies).
Secondary antibodies for immunofluorescence were Alexa
Orange-Red 546 nm and Alexa far red 633 nm (Invitrogen).
Other reagents were as follows: N-acetyl cysteine (NAC)
was from Sigma, 2-(N-[7-nitrobenz-2-oxa-1,3-diazol-4-yl]
amino)-2-deoxy-D-glucose
(2-NBDG),
4,6-diamidino2-phenylindole (DAPI) were from Invitrogen. The CellROX
assay for measuring reactive oxygen species was from
Invitrogen.
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Figure 15. Diverse oncogenic stimuli metabolically rewire the microenvironment, via a common mechanism. (A) Oxidative stress and inflammation reprogram the microenvironment. Here, we show that activation of
Ras or the innate immune response in epithelial cancer cells are both sufficient to actively induce metabolic reprogramming of the tumor microenvironment. ROS production and/or cytokine release drives oxidative
stress in adjacent cancer-associated fibroblasts. Oxidative stress in myofibroblasts then mediates the induction of stromal aerobic glycolysis, i.e.,
“metabolic symbiosis” or the “reverse Warburg effect”. Thus, diverse epithelial oncogenes (H-Ras [G12V] and NFkB [p65]) induce oxidative stress
in the tumor stroma. MCT1 and MCT4 are markers of metabolic symbiosis. (B) Oncogenic stimuli converge on stromal MCT4. HaCaT cells which
harbor activated oncogenes gain the ability to glycolytically reprogram
the tumor microenvironment, via the induction of oxidative stress in
cancer-associated fibroblasts. Thus, diverse oncogenes (Ras and NFkB)
act via a common mechanism (oxidative stress), to upregulate MCT4 in
the tumor stroma. As MCT4 controls the “energy” supply for cancer cells,
this makes MCT4 an attractive target, for new therapeutic interventions
aimed at “starving” tumor cells. Similarly, other pro-oncogenic stimuli,
such as loss of BRCA1, TGF-β secretion, and ethanol, as well as ROS and
hydrogen peroxide production, all converge on MCT4 upregulation in
the tumor stromal compartment. In addition, all these pro-oncogenic
stimuli (RAS, NFkB, BRCA1 loss, TGF-β, ROS/H2O2, and ethanol) also drive
a loss of stromal Cav-1 expression in cancer associated fibroblasts. Thus,
Cav-1 and MCT4 are stromal biosensors of the transition to malignancy.

Cell cultures
The HaCaT cancer cell lines were provided by Dr Ulrich
Rodeck and experiments were performed in the recommended
complete growth medium (DMEM with 10% FBS and Penicillin
100 units/mL-Streptomycin 100 µg/mL). Human skin fibroblasts (BJ-1) immortalized with the telomerase reverse transcriptase catalytic domain (hTERT) were originally purchased from
Clontech, Inc, and clones were generated with either GFP or RFP
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overexpression. BJ-1-GFP or BJ-1-RFP fibroblasts were cultured
in HaCaT complete growth media. After 24 h, the media was
changed to DMEM with 10% nuserum and penicillin 100 units/
mL-streptomycin 100 µg/mL.
Co-cultures of HaCaT cells and fibroblasts
BJ-1 fibroblasts overexpressing GFP or RFP and one of
the HaCaT cell lines (HaCaT-CTRL, HaCaT-Ras(G12V),
HaCaT-p65) were plated on glass coverslips in 12-well plates in 1
ml of complete media. Epithelial cells were plated within 2 h of
fibroblast plating. The total number of cells per well was 1 × 105.
Experiments were performed at a 5:1 fibroblast-to-epithelial cell
ratio. As controls, homotypic mono-cultures of fibroblasts and
epithelial cells were seeded using the same number of cells as the
total corresponding co-cultures. Cells were maintained at 37 °C
in a humidified atmosphere containing 5% CO2.
Co-cultures of HaCaT-control cells and HaCaT-Ras cells
HaCaT-Ras cells overexpressing RFP and HaCaT-Control cell
lines were plated onto glass coverslips in 12-well plates in 1 ml
of complete media. Both cell lines were plated within 2 h of the
one being plated. The total number of cells per well was 1 × 105.
Experiments were performed at a 5:1 HaCaT-Control -to-HaCaTRas cell ratio. As controls, homotypic mono-cultures of HaCaTControl and HaCaT-Ras cells were seeded using the same number
of cells as the total corresponding co-cultures. Cells were maintained at 37 °C in a humidified atmosphere containing 5% CO2.
Flow cytometric analysis
HaCaT cells were plated in co-culture with BJ-1 fibroblasts
(which were either GFP [+] or RFP[+]) or plated in mono-culture. Cells were grown for a total culture duration of 4 d. Then,
to isolate the GFP(+) or RFP(+) BJ-1 cell population, co-cultured
cells were sorted using a 488 nm and a 543 nm laser. As a critical
control, mono-cultures of Hacat cells, which are GFP(−), and
BJ-1 fibroblast cells, which are GFP (+) or RFP (+), were sorted
in parallel.
Measurement of reactive oxygen species
CellROX (cat #C10422, Invitrogen) is a cell-permeable dye
used to measure intracellular ROS. CellROX is non-fluorescent
in a reduced state. When oxidized by reactive oxygen species
witihin cells it has high fluorescence, with absorption/emission
maxima of ~644–665 nm. The fluorescence method was used
according to the manufacturer’s instructions. Briefly, BJ-1 fibroblasts which were RFP(+) were cultured homotypically or in coculture with HaCaT cells. Cells were then incubated with 5 μM
CellROX in DMEM with 10% FBS for 30 min at 37 °C. Cells
were then washed in PBS ×3, harvested, and re-suspended in 500
μL of PBS. Cells were analyzed by flow cytometry using an RFP
signal detector to distinguish fibroblasts from HaCaT cells (fibroblasts are the RFP[+] population) and an APC signal detector to
measure levels of intracellular reactive oxygen species.
Measurement of glucose uptake
Glucose uptake was performed using 2-NBDG. HaCaT
cells in homo-typic culture or co-cultured with BJ-1 fibroblasts
(RFP[+]) were cultured for 4 d. Then, the cells were incubated
with 2-NBDG solution (diluted in phenol red free DMEM with
10% FBS to a final concentration of 250 μM) for 30 min at 37
°C. All subsequent steps were performed in the dark. Cells were
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then washed in PBS, harvested, and re-suspended in 500 μL of Briefly, the channel was split into 8-bit single color images.
PBS. Cells were then analyzed by flow cytometry using a GFP Polygon selection was used to delineate the cells so as to measure
signal detector with excitation wavelength of 488 nm and emis- cell fluorescence intensity and area. Quantification was expressed
sion of 530 nm (to detect 2-NBDG), and an RFP signal detector as intensity per unit area intensity/area(pixel2). Different condiwith excitation wavelength of 496 nm and emission of 615 (to tions were compared by Student t test.
detect RFP-positive BJ-1 cells). Thus, HaCaT cells in co-culture
Apoptosis measurement
were the RFP-negative population.
Cell death was quantified by flow cytometry using propidium
Mitochondrial activity
iodide and Annexin-V-APC, as previously described, with minor
To measure mitochondrial activity, cells were stained with modifications.23 Briefly, HaCaT cells and BJ-1 cells were plated
MitoTracker Orange (CMTMRos cat #M7510, Invitrogen), in 12-well plates, with the BJ-1 cells being GFP(+). The day after,
whose accumulation in mitochondria is dependent upon mem- media was changed to DMEM with 10% NuSerum. After a total
brane potential. Briefly, HaCaT cells were cultured alone for 3 of 4 d in culture, cells were collected by centrifugation and redays in DMEM with 10% NuSerum. Cells were then incubated suspended in 500 μL of Annexin-V binding buffer. Then, the
with pre-warmed MitoTracker staining solution (diluted in serum annexin V-APC conjugate (BD Biosciences 550474) (4 μL) and
free DMEM to a final concentration of 10 nM) for 10 min at 37 propidium iodide (1 μL) was added and incubated in the dark at
°C. All subsequent steps were performed in the dark. Cells were room temperature for 5 min. Cells were then analyzed by flow
washed in PBS, harvested, and re-suspended in 500 μL of PBS. cytometry using a GFP signal detector (to detect BJ-1-GFP cells),
Cells were then analyzed by flow cytometry using a GFP signal a PE Texas Red signal detector and an APC signal detector.
detector with excitation wavelength of 488 nm and emission of
Beta-galactosidase assay
530 nm (to detect GFP-positive fibroblasts), and a PE Texas Red
Assays were performed as previously described.50 Briefly,
signal detector with excitation wavelength of 496 nm and emis- 240 000 cells were seeded per well in 6-well plates in DMEM
sion of 615 (to detect MitoTracker). Data analysis was performed with 10% FBS and 1% P/S. The next day, the media was
using FlowJo 8.8 software.
changed to DMEM with 10% Nu serum. Cells were then incuImmunocytochemistry
bated at 37 °C with 5% CO2, under normal conditions. Then,
Cells were fixed after 4 days of culture. Then, the ICC proto- the cells were trypsinized, centrifuged, and counted to obtain
col was performed as previously described, with minor modifica- 106 cells. Afterwards, cells were treated according the manufactions.56 Briefly, cells were fixed for 30 min at room temperature turer’s instructions, using the FluoReporter lacZ Flow Cytometry
in 2% para-formaldehyde diluted in PBS, after which they were Kit (Molecular probes, #F-1930). Assay results were evaluated by
permeabilized with cold methanol at −20 °C for 5 min. The cells flow-cytometry analysis.
were rinsed with PBS with 0.1 mM calcium chloride and 1 mM
Disclosure of Potential Conflicts of Interest
magnesium chloride (PBS/CM). Then, cells were incubated with
NH4Cl in PBS to quench free aldehyde groups. Rinsing with
No potential conflicts of interest were disclosed.
PBS/CM was followed by blocking with immunofluorescence
(IF) buffer (PBS, 1% BSA, 0.1% Tween 20) for 1 h at room temperature. Primary anti-MCT4 and TOMM20 antibodies were
incubated in IF buffer for 1 h at room temperature.
After washing with IF buffer (3×, 10 min each),
cells were incubated for 30 min at room temperature with fluorochrome-conjugated anti-rabbit and
anti-mouse secondary antibodies diluted in IF buffer. Finally, slides were washed at room temperature
with IF buffer (3×, 10 min each), rinsed with PBS/
CM and counter-stained with DAPI (1 μg/ml) in
PBS and mounted with Prolong Gold anti-fade
reagent.
Confocal microscopy
Images were collected with a Zeiss LSM510 meta
confocal system using a 405 nm diode excitation
laser with a band pass filter of 420–480 nm, a 488
nm Argon excitation laser with a band pass filter of
505–550 nm, a 543 nm HeNe1 excitation laser with
a 561–604 nm filter and a 633 nM HeNe2 excitation laser with a 657–754 nm filter. Images were
acquired with a 40× objective. Immunofluorescence
Figure 16. Understanding why cancer behaves as a wound that does not heal. Oncogenic
stress stimulates a common metabolic response to “injury” in the tumor microenvironstaining image quantitation was performed using
ment. Four steps or events are outlined, leading to “metabolic symbiosis”. This idea is
ImageJ 1.46 (National Institutes of Health,).
consistent with the hypothesis that cancer behaves as a wound that does not heal.
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